Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Mild Cognitive Impairment, Alzheimer's Disease

In brief

This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or early Alzheimer's disease.

Key facts

Study ID
NCT01661673
Run by
FORUM Pharmaceuticals Inc
People needed
52
Starts
2012-11-01
Last updated by the study team
2014-01-13

Who can join

Age: 45 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.